Bruker Corporation (BRKR) appears in good shape, with its shares rising 20.7% since the fourth-quarter earnings release. The company continues to benefit from its innovative, high-performance product lines. The AI-driven semiconductor and advanced packaging metrology tools in the NANO group are performing well. The Zacks Rank #2 (Buy) stock has increased 20.7% since the last earnings release compared with the industry’s rise of 15%. The Medical sector has gained 3.6% in the said time frame. The company has ...

Bruker Corporation (BRKR) recently announced its progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows at the 20 US Human Proteome Organization Congress 2024. The advances include improved machine-learning de novo sequencing (Novor V2.0), a novel high-performance monitoring digital-twin software (TwinScape), the new glyco-PASEF method for high-sensitivity glycopeptide analysis and access to Spectronaut 18 for users of Bruker ProteoScape — a GPU-powered software for rea ...

收购信息 - Bruker Corporation成功完成收购Chemspeed Technologies AG，标志着Bruker在科学软件、研发和质量控制数字化以及实验室自动化领域的扩张[1] - Chemspeed将作为独立业务继续在Bruker内部运营，保持对行业领先的自动化实验室解决方案和客户服务的承诺[2] - Bruker致力于在自动化研发和质量控制实验室解决方案、实验室数字化和科学软件领域进行战略扩张和创新[2] 预期收益 - 预计Chemspeed在2024年剩余三个季度将接近盈亏平衡，每个季度约有1000万美元的收入[2] - 到2025年预计Chemspeed将对Bruker的非GAAP每股收益有2-3美分的增值[2] 公司使命 - Bruker通过高性能科学仪器和高价值分析和诊断解决方案帮助科学家进行突破性发现，提高人类生活质量[3]

Bruker Corporation (BRKR) recently entered into a definitive share purchase agreement with TecFin S.à r.l., a controlled affiliate of the pre-eminent private equity firm PAI Partners, to acquire ELITechGroup. However, the €870 million cash transaction excludes the carved-out ELITech clinical chemistry business. The transaction is expected to close in the second quarter of 2024, subject to regulatory approvals, the carve-out of the clinical chemistry business and other customary closing conditions. Upon clos ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission File Number 000-30833 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-3110160 (State or other jurisdi ...

Bruker公司产品进展 - Bruker公司的CALID集团最近取得了不错的进展，主要是因为对差异化仪器的强劲需求[2] - Bruker公司在2023年推出了timsTOF Ultra，提供了市场领先的灵敏度和吞吐量，扩展了肽覆盖范围，并在无偏见的4D单细胞系和组织蛋白质组学中提供更准确的定量[3] - Bruker公司在2023年第四季度推出了Hysitron TI 990 TriboIndenter，具有卓越的性能、自动化和生产力，用于纳米力学测试[7] Bruker公司业务发展 - Bruker公司早前收购了著名的功能性细胞生物学公司PhenomeX，这一交易扩大了Bruker在转化研究、临床研究和生物制药领域的业务，并有助于其Project Accelerate 2.0计划[8] Bruker公司财务状况 - Bruker公司在2023年第四季度的非GAAP毛利率表现受到外汇波动的不利影响，预计这将在2024年第一季度继续对Bruker构成压力，导致较软的运营利润预测[10] - Bruker公司的成本增长导致毛利率下降，这可能会影响公司的运营结果和现金流[12]

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Citi 2024 Unplugged Medtech and Life Sciences Access Day in New York City Thursday, February 29, 2024, at 8:45 a.m. Eastern Time TD Cowen 44th Annual Health Care Conference in Boston, MA Monday, March 4, 2024, at 9:50 a.m. Eastern Time Live audiovisual webcasts of the presentations will be availabl ...

仪器-科学行业 - 仪器-科学行业受益于不断增加的医疗支出，主要受到人口老龄化和制药和生命科学终端市场持续创新的推动[1] - 行业参与者如Mettler-Toledo International (MTD)和Bruker (BRKR)受益于新型生物药物的不断增长的测试需求[1] - 行业面临挑战性的宏观经济条件，欧洲低PMI读数，乌克兰战争和中东冲突等问题[1] - 仪器-科学行业包括提供科学仪器、分析工具、诊断解决方案、精密仪器和服务以及测试和传感器解决方案的公司[2] - 大多数行业参与者受到全球严格的监管审查，必须遵守美国食品药品监督管理局和美国环境保护局的规定，以及其他全球监管机构的规定[3] - 行业受益于强劲的终端市场需求，特别是来自生命科学、制药和学术市场的需求增长[4] - 社会经济因素如人口老龄化和不断增加的环境法规推动了对科学测量解决方案的需求[5] - 行业受益于对中国和印度等新兴经济体的不断增加的曝光度[6] - 行业排名显示乐观前景，位于Zacks行业排名第8位，属于250个Zacks行业中的前3%[8] - 行业在过去一年表现不佳，与更广泛的Zacks计算机和技术部门以及标准普尔500指数相比表现不佳[12] - 行业当前估值较高，前12个月的市盈率为28.76X，高于标准普尔500的20.71X和Zacks计算机和技术部门的21.29X[13] - Mettler-Toledo和Bruker是值得关注的两家科学仪器供应商，前者受益于食品零售领域的强劲势头，后者在创新组合方面表现出色[15][17]

纳斯达克100指数表现 - 纳斯达克100指数在2024年表现强劲，几乎每周都在创下新高[1] - 一些投资者担心可能存在泡沫，但纳斯达克仍有一些具有投资潜力的股票[2] Bruker公司 - Bruker是一家生命科学公司，主要以其核磁共振（NMR）光谱仪等实验室设备而闻名[3] - Bruker在过去几年销售放缓，但最近宣布了出色的财报[4] - Bruker的Bruker Energy & Supercon Technologies “BEST”部门在超导体领域迅速增长[5] Honeywell公司 - Honeywell是一家工业公司，专注于工业自动化，为公司如亚马逊等提供基础设施支持[6] - Honeywell不断推出前沿创新，如量子计算，并将该部门拆分为Quantinuum公司[7] Pepsico公司 - Pepsico是一家软饮料和零食巨头，虽然股价未见明显上涨，但仍是一家稳健增长的蓝筹股[8]

Bruker Corporation (BRKR) delivered adjusted earnings per share (EPS) of 70 cents in the fourth quarter of 2023, down 5.4% year over year. The figure exceeded the Zacks Consensus Estimate by 7.7%. The adjustments include expenses related to the amortization of purchased intangibles, acquisition-related costs and restructuring costs, among others. GAAP EPS in the quarter was $1.41, surging 113.6% from the year-earlier quarter’s figure of 66 cents. For the full year, adjusted earnings were $2.58 per share, ri ...